Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 1Endocrine 1Dermatologic 1

Conditions

Neuroendocrine Tumors Metastatic to the Liver 1Melanoma 1

Interventions

Cisplatin 509Cyclophosphamide 360Carboplatin 352Radiotherapy 350Capecitabine 329Paclitaxel 325Oxaliplatin 324Gemcitabine 319Docetaxel 311Fluorouracil 283Drug Therapy 243apatinib 242Bevacizumab 229camrelizumab 214Etoposide 200Irinotecan 176Doxorubicin 175Leucovorin 161Dexamethasone 160sintilimab 142pembrolizumab 138anlotinib 136Pemetrexed 136Cytarabine 136toripalimab 129Neoadjuvant Therapy 122S 1 (combination) 120Vincristine 119Rituximab 117Radiosurgery 117

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Interventional × Rose Bengal B × Clear all
NCT02557321 2023-11-21

PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

Provectus Pharmaceuticals

Phase 1/2 Unknown
50 enrolled
Dermatologic

Melanoma

NCT02693067 2023-02-08

A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver

Provectus Pharmaceuticals

Phase 1 Unknown
12 enrolled
EndocrineNET

Neuroendocrine Tumors Metastatic to the Liver

Data powered by HemOnc (CC BY 4.0) Colophon âš¡